What is Immunostics?
Immunostics is a developer, manufacturer, and seller of FDA-approved diagnostic kits and reagents for microbiological, serological, and immunological applications. The company's core offerings include flagship products designed to detect fecal occult blood, a key indicator for colorectal cancer and other gastro-intestinal disorders. With a portfolio bolstered by several U.S. and international patents and trademarks, Immunostics has solidified its niche in the healthcare diagnostics sector, focusing on critical screening technologies.
How much funding has Immunostics raised?
Immunostics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Immunostics?
The substantial capital infusion, particularly the recent strategic investment, positions Immunostics for accelerated expansion and potential market leadership. This funding is likely to be directed towards scaling manufacturing capabilities, enhancing research and development for new diagnostic solutions, and broadening its market reach both domestically and internationally. The company's focus on essential diagnostic tools suggests a strategic direction aimed at addressing significant public health needs, with future growth potentially involving strategic partnerships or further product line diversification.
See full Immunostics company page
